

References

- Committee for Practice Guidelines (CPG). European Society of Cardiology: recommendations for Task Force creation and report production. A document for Task Force members and expert panels responsible for the creation and production of Guidelines and Expert Consensus Documents. <http://www.escardio.org/knowledge/guidelines/Rules/>
- Soler-Soler J, Galve E. Worldwide perspective of valve disease. *Heart* 2000;**83**:721–725.
- Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. *Eur Heart J* 2003;**24**:1231–1243.
- Rizvi SFH, Khan MA, Kundi A, Marsh DR, Samad A, Pasha O. Current status of rheumatic heart diseases in rural Pakistan. *Heart* 2004;**90**:394–399.
- Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Whitney Lytle B, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists. *J Am Coll Cardiol* 2006;**48**:e1–e148.
- Prendergast BD, Banning AP, Hall RJ. Valvular heart disease: recommendations for investigation and management. Summary of guidelines produced by a working group of the British Cardiac Society and the Research Unit of the Royal College of Physicians. *J R Coll Physicians Lond* 1996;**30**:309–315.
- Classen M, Dierkesmann R, Heimpel H, Kalden JR, Koch KM, Meyer J, Theiss W, Ziegler R. Rationale Diagnostik und Therapie in der inneren Medizin. Ein Beitrag zur Qualitätssicherung in Klinik und Praxis. München: Urban und Fischer; 1999.
- Azpitarte J, Alonso AM, Garcia Gallego F, Gonzalez Santos JM, Pare C, Tello A. Guías de practica clinica de la Sociedad Espanola de Cardiologia en valvulopatias. *Rev Esp Cardiol* 2000;**53**:1209–1278.
- Tribouilloy C, De Guevigny G, Acar C, Chassignolle JF, Cormier B, Habib G, Hanania G, Iung B, Leguerrier A, Marchand M, Michel PL, Obadia JF, Roudaut R, Vahanian A, Villemot JP, Warembourg H. Recommendations de la Société Française de Cardiologie concernant la prise en charge des valvulopathies acquises et des dysfonctions de prothèse valvulaire. Indications opératoires et interventionnelles. *Arch Mal Coeur* 2005;**98**(Suppl.):5–61.
- Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, Soler-Soler J, Thieme G, von Graevenitz A, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lindahl B, Mazzotta G, Morais J, Smiseth OA, Lekakis J, Vahanian A, Delahaye F, Parkhomenko A, Filipatos G, Aldershvile J, Vardas P, Task Force Members on Infective Endocarditis of the European Society of Cardiology, ESC Committee for Practice Guidelines (CPG), Document Reviewers. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary: The Task Force on Infective Endocarditis of the European Society of Cardiology. *Eur Heart J* 2004;**25**:267–276.
- Deanfield J, Thaulow E, Warnes C, Webb G, Kolbel F, Hoffman A, Sorenson K, Kaemmerer H, Thilen U, Bink-Boelkens M, Iserin L, Dailento L, Silove E, Redington A, Vouhe P, Priori SG, Alonso MA, Blanc JJ, Budaj A, Cowie M, Deckers JW, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth O, Trappe HJ. Management of grown up congenital disease. The Task Force on the management of grown up congenital disease of the European Society of Cardiology. *Eur Heart J* 2003;**24**:1035–1084.
- Gohlke-Barwolf C, Acar J, Oakley C, Butchart E, Burckhart D, Bodnar E, Hall R, Delahaye JP, Horstkotte D, Krayenbuhl HP, Krzeminska-Pakula M, Kremer R, Samama MM. Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 1995;**16**:1320–1330.
- Iung B, Gohlke-Barwolf C, Tornos P, Tribouilloy C, Hall R, Butchart E, Vahanian A, Working Group on Valvular Heart Disease. Recommendations on the management of the asymptomatic patient with valvular heart disease. Working Group Report on behalf of the Working Group on Valvular Heart Disease. *Eur Heart J* 2002;**23**:1253–1266.
- Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Lepout C, Hall RJ, Vahanian A, Working Groups on Valvular Heart Disease, Thrombosis, Cardiac Rehabilitation, Exercise Physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. *Eur Heart J* 2005;**26**:2463–2471.
- Vahanian A, Iung B, Pierard L, Dion R, Pepper J. Valvular heart disease. In: Camm AJ, Lüscher TF, Serruys PW, eds. *The ESC Textbook of Cardiovascular Medicine*. Malden/Oxford/Victoria: Blackwell Publishing Ltd; 2006. p625–670.
- Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ, Task Force for the Diagnosis Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: Executive Summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005;**26**:1115–1140.
- Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA, for the Doppler Quantification Task Force of the Nomenclature Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. *J Am Soc Echocardiogr* 2002;**15**:167–184.
- Bermejo J, Odreman R, Feijoo J, Moreno MM, Gomez-Moreno P, Garcia-Fernandez MA. Clinical efficacy of Doppler-echocardiographic indices of aortic valve stenosis: a comparative test-based analysis of outcome. *J Am Coll Cardiol* 2003;**41**:142–151.
- Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ, American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. *J Am Soc Echocardiogr* 2003;**16**:777–802.
- Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO, American College of Cardiology, American Heart Association, American Society for Nuclear Cardiology. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2003;**42**:1318–1333.
- Amato MC, Moffa PJ, Werner KE, Ramirez JA. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. *Heart* 2001;**86**:381–386.
- Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. *Eur Heart J* 2005;**26**:1309–1313.
- Pelliccia A, Fagard R, Bjørnstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson B, Carre F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thieme G. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. *Eur Heart J* 2005;**26**:1422–1445.
- Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischaemic left ventricular dysfunction. *Circulation* 2003;**108**:1713–1717.
- Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. *Circulation* 2005;**112**(Suppl. 1):I-377–I-382.
- Lee R, Haluska B, Leung DY, Case C, Mundy J, Marwick TH. Functional and prognostic implications of left ventricular contractile reserve in patients with asymptomatic severe mitral regurgitation. *Heart* 2005;**91**:1407–1412.

27. Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C, Dehant P, Tribouilloy C, Gueret P. Low-gradient aortic stenosis, operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. *Circulation* 2003;108:319–324.
28. Messika-Zeitoun D, Aubry MC, Detaint D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Breen JF, Scott C, Tajik AJ, Enriquez-Sarano M. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. *Circulation* 2004;110:356–362.
29. Westenberg JJ, Doornbos J, Versteegh MI, Bax JJ, van der Geest RJ, de Roos A, Dion RA, Reiber JH. Accurate quantitation of regurgitant volume with MRI in patients selected for mitral valve repair. *Eur J Cardiothorac Surg* 2005;27:462–466.
30. Bergler-Klein J, Klačar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. *Circulation* 2004;109:2302–2308.
31. Detaint D, Messika-Zeitoun D, Avierinos JF, Scott C, Chen H, Burnett JC Jr, Enriquez-Sarano M. B-type natriuretic peptide in organic mitral regurgitation. Determinants and impact on outcome. *Circulation* 2005;111:2391–2397.
32. Omran H, Schmidt H, Hackenbroch M, Illien S, Bernhardt P, von der Recke G, Fimmers R, Flacke S, Layer G, Pohl C, Luderitz B, Schild H, Sommer T. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. *Lancet* 2003;361:1241–1246.
33. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlke-Bärwolf C, Boersma E, Ravaud P, Vahanian A. Decision making in elderly patients with severe aortic stenosis: why are so many denied surgery? *Eur Heart J* 2005;26:2714–2720.
34. Avierinos JF, Gersh BJ, Melton LJ III, Bailey KR, Shub C, Nishimura RA, Tajik AJ, Enriquez-Sarano M. Natural history of mitral valve prolapse in the community. *Circulation* 2002;106:1355–1361.
35. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19 030 patients. *Eur J Cardiothorac Surg* 1999;15:816–823.
36. Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR, Shroyer ALW, Grover FL. Prediction of operative mortality after valve replacement surgery. *J Am Coll Cardiol* 2001;37:885–892.
37. Ambler G, Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor KM. Generic, simple risk stratification model for heart valve surgery. *Circulation* 2005;112:224–231.
38. Jin R, Grunkemeier GL, Starr A, the Providence Health System Cardiovascular Study Group. Validation and refinement of mortality risk models for heart valve surgery. *Ann Thorac Surg* 2005;80:471–479.
39. Roques F, Nashef SAM, Michel P, the EuroSCORE Study Group. Risk factors for early mortality after valve surgery in Europe in the 1990s: lessons from the EuroSCORE pilot program. *J Heart Valve Dis* 2001;10:572–578.
40. Judge DP, Dietz HC. Marfan's syndrome. *Lancet* 2005;366:1965–1976.
41. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA. Yearly rupture or dissection rates for thoracic aneurysms: simple prediction based on size. *Ann Thorac Surg* 2002;73:17–27.
42. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany Ch J, Bailey KR, Seward JB. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. *J Am Coll Cardiol* 1997;30:746–752.
43. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice. A long term follow up study. *Circulation* 1999;99:1851–1857.
44. Borer JS, Hochreiter C, Herrold EM, Supino P, Aschermann M, Wencker D, Devereux RB, Roman MJ, Zulu M, Kligfield P, Isom OW. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. *Circulation* 1998;97:525–534.
45. Tarasoutchi F, Grinberg M, Spina GS, Sampaio RO, Cardoso LF, Rossi EG, Pomerantzeff P, Laurindo F, da Luz PL, Ramires JA. Ten-year laboratory follow up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology. *J Am Coll Cardiol* 2003;41:1316–1324.
46. Borer JS, Bonow RO. Contemporary approach to aortic and mitral regurgitation. *Circulation* 2003;108:2432–2438.
47. Roman MJ, Devereux RB, Niles NW, Hochreiter C, Kligfield P, Sato N, Spitzer MC, Borer JS. Aortic root dilatation as a cause of isolated severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns and relation to left ventricular hypertrophy and function. *Ann Intern Med* 1987;106:800–807.
48. Silverman DI, Gray J, Roman MJ, Bridges A, Burton K, Boxer M, Devereux RB, Tsipouras P. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. *J Am Coll Cardiol* 1995;26:1062–1067.
49. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, Coe MP, Kopf GS, Elefteriades JA. Novel measurements of relative aortic size predicts rupture of thoracic aortic aneurysm. *Ann Thorac Surg* 2006;81:169–177.
50. Keane MG, Wiegers SE, Plappert T. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. *Circulation* 2000;102(Suppl. III):III35–III39.
51. STS national database: STS U.S. cardiac surgery database: 1997 Aortic valve replacement patients: preoperative risk variables. Chicago, Society of Thoracic Surgeons; 2000. Accessed 10 May 2006. <http://www.ctsnet.org/doc/3031>
52. National Adult Cardiac Surgical Database Report 1999–2000. The United Kingdom Cardiac Surgical Register. Accessed 10 May 2006. <http://www.scts.org/file/NACSDreport2000ukcsr.pdf>
53. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, Enriquez-Sarano M. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. *Circulation* 2002;106:2687–2693.
54. Corti R, Binggeli C, Turina M, Jenni R, Lüscher TF, Turina J. Predictors of long term survival after valve replacement for chronic aortic regurgitation. *Eur Heart J* 2001;22:866–887.
55. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler Soler J. Long term outcome of surgically treated aortic regurgitation: influence of guidelines adherence towards early surgery. *J Am Coll Cardiol* 2006;47:1012–1017.
56. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany Ch, Bailey KR, Seward JB. Aortic regurgitation complicated by extreme left ventricular dilation: long term outcome after surgical correction. *J Am Coll Cardiol* 1996;27:670–677.
57. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic patients with Marfan syndrome. *Circulation* 2005;111:e150–e157.
58. Ergin MA, Spielvogel D, Apaydin A, Lansman SL, McCullough JN, Galla JD, Griepp RB. Surgical treatment of the dilated ascending aorta: when and how? *Ann Thorac Surg* 1999;67:1834–1839.
59. Zehr KJ, Orszulak TA, Mullany CJ, Matloobi A, Daly RC, Dearani JA, Sundt TM III, Puga FJ, Danielson GK, Schaff HV. Surgery for aneurysms of the aortic root: a 30-year experience. *Circulation* 2004;110:1364–1371.
60. Enriquez-Sarano M, Tajik AJ. Clinical practice. Aortic regurgitation. *N Engl J Med* 2004;351:1539–1546.
61. Scognamiglio R, Negut C, Palisi M, Fasoli G, Dalla-Volta S. Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. *J Am Coll Cardiol* 2005;45:1025–1030.
62. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler Soler J. Long term vasodilator therapy in patients with severe aortic regurgitation. *N Engl J Med* 2005;353:1324–1329.
63. Shores J, Berger KR, Murphy EA, Peyeritz RE. Progression of aortic dilatation and the benefit of long term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994;330:1335–1341.
64. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilatation in patients with Marfan syndrome. *Am J Cardiol* 2005;95:1125–1127.
65. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. *J Am Coll Cardiol* 1997;29:630–634.
66. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med* 1999;341:142–147.
67. deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ, Grayburn PA. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. *Am J Cardiol* 1995;75:191–194.
68. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST, Holmes DR Jr. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. *Circulation* 2002;106:809–813.

69. Feuchtnner GM, Dichtl W, Friedrich GJ, Frick M, Alber H, Schachner T, Bonatti J, Mallouhi A, Frede T, Pachinger O, zur Nedden D, Muller S. Multislice computed tomography for detection of asymptomatic valvular aortic stenosis and quantification of severity. *J Am Coll Cardiol* 2006; **47**:1410-1417.
70. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997; **95**:2262-2270.
71. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. *N Engl J Med* 2000; **343**:611-617.
72. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. *Circulation* 2005; **111**:3290-3295.
73. Lund O, Nielsen TT, Emmertsen K, Flo C, Rasmussen B, Jensen FT, Pilegaard HK, Kristensen LH, Hansen OK. Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. *Thorac Cardiovasc Surg* 1996; **44**:289-295.
74. Kvidal P, Bergström R, Hörte LG, Ståhle E. Observed and relative survival after aortic valve replacement. *J Am Coll Cardiol* 2000; **35**:747-756.
75. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. *J Am Coll Cardiol* 2000; **36**:1131-1141.
76. Vahanian A, Palacios IF. Percutaneous approaches to valvular disease. *Circulation* 2004; **109**:1572-1579.
77. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Nercolini D, Tapiero S, Litzler PY, Bessou JP, Babaliaros V. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. *J Am Coll Cardiol* 2006; **47**:1214-1223.
78. Connolly HM, Oh JK, Schaff HV, Roger VL, Osborn SL, Hodge DO, Tajik AJ. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. *Circulation* 2000; **101**:1940-1946.
79. Pereira JJ, Lauer MS, Bashir M, Afridi I, Blackstone EH, Stewart WJ, McCarthy PM, Thomas JD, Asher CR. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. *J Am Coll Cardiol* 2002; **39**:1356-1363.
80. Otto CM. Timing of aortic valve surgery. *Heart* 2000; **84**:211-218.
81. Mohler ER III. Mechanisms of aortic valve calcification. *Am J Cardiol* 2004; **94**:1396-1402.
82. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. *J Am Coll Cardiol* 2002; **40**:1723-1730.
83. Rosenhek R, Rader F, Lohö N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. *Circulation* 2004; **110**:1291-1295.
84. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. *Arch Intern Med* 2005; **165**:858-862.
85. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005; **352**:2389-2397.
86. Pereira JJ, Balaban K, Lauer MS, Lytle B, Thomas JD, Garcia MJ. Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery. *Am J Med* 2005; **118**:735-742.
87. Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, Cohn LH. Staged initial percutaneous coronary intervention followed by valve surgery ("hybrid approach") for patients with complex coronary and valve disease. *J Am Coll Cardiol* 2005; **45**:14-18.
88. Edwards MB, Taylor KM. Outcomes in nanogenarians after valve replacement operation. *Ann Thorac Surg* 2003; **75**:830-834.
89. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, David TE. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? *J Thorac Cardiovasc Surg* 2004; **128**:677-683.
90. Enriquez-Sarano M, Bailey KR, Seward JB, Tajik AJ, Krohn MJ, Mays JM. Quantitative Doppler assessment of valvular regurgitation. *Circulation* 1993; **87**:841-848.
91. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. *N Engl J Med* 2005; **352**:875-883.
92. Carpentier A. Cardiac valve surgery—the 'French correction'. *J Thorac Cardiovasc Surg* 1983; **86**:323-337.
93. Enriquez-Sarano M, Freeman WK, Tribouilloy CM, Orszulak TA, Khandheria BK, Seward JB, Bailey KR, Tajik AJ. Functional anatomy of mitral regurgitation: accuracy and outcome implications of TEE. *J Am Coll Cardiol* 1999; **34**:1129-1136.
94. Monin J-L, Dehant P, Roiron C, Monchi M, Tabet J-Y, Clerc P, Fernandez G, Houel R, Garot J, Chauvel C, Gueret P. Functional assessment of mitral regurgitation by transthoracic echocardiography using standardized imaging planes. *J Am Coll Cardiol* 2005; **46**:302-309.
95. Ling LH, Enriquez-Sarano M, Seward JB, Tajik AJ, Schaff HV, Bailey KR, Frye RL. Clinical outcome of mitral regurgitation due to flail leaflet. *N Engl J Med* 1996; **335**:1417-1423.
96. Grigioni F, Enriquez-Sarano M, Ling LH, Bailey KR, Seward JB, Tajik AJ, Frye RL. Sudden death in mitral regurgitation due to flail leaflet. *J Am Coll Cardiol* 1999; **34**:2078-2085.
97. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Bailey KR, Tajik AJ, Frye RL. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical implications. *Circulation* 1999; **99**:400-405.
98. Lee EM, Shapiro LM, Wells FC. Superiority of mitral valve repair in surgery for degenerative mitral regurgitation. *Eur Heart J* 1997; **18**:655-663.
99. Thamilarasan M, Griffin B. Choosing the most appropriate valve operation and prosthesis. *Cleveland Clin J Med* 2002; **69**:668-703.
100. Enriquez-Sarano M, Schaff HV, Orszulak TA, Tajik AJ, Bailey KR, Frye RL. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. *Circulation* 1995; **91**:1022-1028.
101. Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P, Chatellier G, Chauvaud S, Fabiani JN, Carpentier A. Very long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. *Circulation* 2001; **104**:18-111.
102. Otto CM, Salerno CT. Timing of surgery in asymptomatic mitral regurgitation. *N Engl J Med* 2005; **352**:928-929.
103. Enriquez-Sarano M, Schaff HV, Frye RL. Mitral regurgitation: what causes the leakage is fundamental to the outcome of valve repair. *Circulation* 2003; **108**:253-256.
104. Raanani E, Albage A, David TE, Yau TM, Armstrong S. The efficacy of the Cox/maze procedure combined with mitral valve surgery: a matched control study. *Eur J Cardiothorac Surg* 2001; **19**:438-442.
105. Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. *J Am Coll Cardiol* 2005; **46**:2134-2140.
106. Webb JG, Harenek J, Munt BI, Kimblad PO, Chandavimol M, Thompson CR, Mayo JR, Solem JO. Percutaneous transvenous mitral annuloplasty: initial human experience with device implantation in the coronary sinus. *Circulation* 2006; **113**:851-855.
107. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. *Circulation* 2006; **113**:2238-2244.
108. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation—Executive Summary: a report by the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). *Eur Heart J* 2006; **27**:1976-2030.
109. Grayburn PA. Vasodilator therapy for chronic aortic and mitral regurgitation. *Am J Med Sci* 2000; **320**:202-208.
110. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications

- with quantitative Doppler assessment. *Circulation* 2001;103:1759-1764.
111. Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. *Circulation* 2005;112:745-758.
112. Piérard LA, Lancellotti P. The role of ischaemic mitral regurgitation in the pathogenesis of acute pulmonary edema. *N Engl J Med* 2004;351:1627-1634.
113. Lebrun F, Lancellotti P, Piérard LA. Quantitation of functional mitral regurgitation during bicycle exercise in patients with heart failure. *J Am Coll Cardiol* 2001;38:1685-1692.
114. Lancellotti P, Gérard P, Piérard L. Long term outcome of patients with heart failure and dynamic mitral regurgitation. *Eur Heart J* 2005;26:1528-1532.
115. Pu M, Thomas JD, Gillinov MA, Griffin BP, Brunken RC. Importance of ischaemic and viable myocardium for patients with chronic ischaemic mitral regurgitation and left ventricular dysfunction. *Am J Cardiol* 2003;92:862-864.
116. Iung B. Management of ischaemic mitral regurgitation. *Heart* 2003;89:459-464.
117. Glower DD, Tuttle RH, Shaw LK, Orozco RE, Rankin JS. Patient survival characteristics after routine mitral valve repair for ischaemic mitral regurgitation. *J Thorac Cardiovasc Surg* 2005;129:860-868.
118. Seipelt RG, Schoendube FA, Vazquez-Jimenez JF, Doerge H, Voss M, Messmer BJ. Combined mitral valve and coronary artery surgery: ischaemic versus non-ischaemic mitral valve disease. *Eur J Cardiothorac Surg* 2001;20:270-275.
119. Bouchard D, Pellerin M, Carrier M, Perrault LP, Page P, Hebert Y, Cartier R, Dyrda I, Pelletier LC. Results following valve replacement for ischaemic mitral regurgitation. *Can J Cardiol* 2001;17:427-431.
120. Braun J, Bax JJ, Versteegh MI, Voigt PG, Holman ER, Klautz RJ, Boersma E, Dion RA. Preoperative left ventricular dimensions predict reverse remodelling following restrictive mitral annuloplasty in ischaemic mitral regurgitation. *Eur J Cardiothorac Surg* 2005;27:847-853.
121. Bax JJ, Braun J, Somer ST, Klautz R, Holman ER, Versteegh MI, Boersma E, Schalijs MJ, van der Wall EE, Dion RA. Restrictive annuloplasty and coronary revascularization in ischaemic mitral regurgitation results in reverse left ventricular remodeling. *Circulation* 2004;110(Suppl.):II103-II108.
122. Gillinov AM, Wierup PN, Blackstone EH, Bishay ES, Cosgrove DM, White J, Lytle BW, McCarthy PM. Is repair preferable to replacement for ischaemic mitral regurgitation? *J Thorac Cardiovasc Surg* 2001;122:1125-1141.
123. Aklog L, Filsofi F, Flores KQ, Chen RH, Cohn LH, Nathan NS, Byrne JG, Adams DH. Does coronary artery bypass grafting alone correct moderate ischaemic mitral regurgitation? *Circulation* 2001;104:168-175.
124. Kim YH, Czer LS, Soukiasian HJ, De Robertis M, Magliato KE, Blanche C, Raissi SS, Mirocha J, Siegel RJ, Kass RM, Trento A. Ischemic mitral regurgitation: revascularization alone versus revascularization and mitral valve repair. *Ann Thorac Surg* 2005;79:1895-1901.
125. Di Donato M, Frigiola A, Menicanti L, Boghdabi A, Badia T, Neagu A, Montericcio V, Ranucci M. Moderate ischaemic mitral regurgitation and coronary artery bypass surgery: effect of mitral repair on clinical outcome. *J Heart Valve Dis* 2003;12:272-279.
126. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K, ESC Committee for Practice Guideline (CPG). Executive Summary of the Guidelines on the Diagnosis and Treatment of Acute Heart Failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005;26:384-416.
127. Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. *Am J Cardiol* 2003;91:538-543.
128. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. *J Thorac Cardiovasc Surg* 1998;115:381-386.
129. Romano MA, Bolling SF. Update on mitral repair in dilated cardiomyopathy. *J Card Surg* 2004;19:396-400.
130. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. *J Am Coll Cardiol* 2005;45:381-387.
131. Mehra MR, Griffith BP. Is mitral regurgitation a viable treatment target in heart failure? The plot just thickened. *J Am Coll Cardiol* 2005;45:388-390.
132. Campos PC, D'Cruz IA, Johnson LS, Malhotra A, Ramanathan KB, Weber KT. Functional valvular incompetence in decompensated heart failure: non-invasive monitoring and response to medical management. *Am J Med Sci* 2005;329:217-221.
133. Krum H. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). *Eur Heart J* 2005;26:2472.
134. Breithardt OA, Sinha AM, Schwammenthal E, Bidaoui N, Markus KU, Franke A, Stellbrink C. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. *J Am Coll Cardiol* 2003;41:765-770.
135. Iung B, Garbarz E, Michaud P, Helou S, Farah B, Berdah P, Michel PL, Cormier B, Vahanian A. Late results of percutaneous mitral commissurotomy in a series of 1024 patients. Analysis of late clinical deterioration: frequency, anatomic findings, and predictive factors. *Circulation* 1999;99:3272-3278.
136. Faletra F, Pezzano A Jr, Fusco R, Mantero A, Corno R, Crivellaro W, De Chiara F, Vitali E, Gordini V, Magnani P, Pezzano A Sr. Measurement of mitral valve area in mitral stenosis: four echocardiographic methods compared with direct measurement of anatomic orifices. *J Am Coll Cardiol* 1996;28:1190-1197.
137. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. *Br Heart J* 1988;60:299-308.
138. Padial LR, Freitas N, Sagie A, Newell JB, Weyman AE, Levine RA, Palacios IF. Echocardiography can predict which patients will develop severe mitral regurgitation after percutaneous mitral valvulotomy. *J Am Coll Cardiol* 1996;27:1225-1231.
139. Lev EI, Sagie A, Vaturi M, Sela N, Battler A, Shapira Y. Value of exercise echocardiography in rheumatic mitral stenosis with and without significant mitral regurgitation. *Am J Cardiol* 2004;93:1060-1063.
140. Diker E, Aydogdu S, Ozdemir M, Kural T, Polat K, Cehreli S, Erdogan A, Goksel S. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. *Am J Cardiol* 1997;77:96-98.
141. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. *Ann Intern Med* 1998;128:885-889.
142. Iung B, Cormier B, Ducimetiere P, Porte JM, Nallet O, Michel PL, Acar J, Vahanian A. Immediate results of percutaneous mitral commissurotomy. A predictive model on a series of 1514 patients. *Circulation* 1996;94:2124-2130.
143. Iung B, Nicoud-Houel A, Fondard O, Akoudad H, Haghighat T, Brochet E, Garbarz E, Cormier B, Baron G, Luxereau P, Vahanian A. Temporal trends in percutaneous mitral commissurotomy over a 15-year period. *Eur Heart J* 2004;25:702-708.
144. Ben Farhat M, Ayari M, Maatouk F, Betbout F, Gamra H, Jarra M, Tiss M, Hammami S, Thaalbi R, Addad F. Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial. *Circulation* 1998;97:245-250.
145. Palacios IF, Sanchez PL, Harrell LC, Weyman AE, Block PC. Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevaluloplasty and postvalvuloplasty variables that predict long-term outcome. *Circulation* 2002;105:1465-1471.
146. Antunes MJ, Vieira H, Ferrao de Oliveira J. Open mitral commissurotomy: the 'golden standard'. *J Heart Valve Dis* 2000;9:472-477.
147. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. *J Am Coll Cardiol* 2000;36:1152-1158.
148. Silarius S, Thinkhamrop B, Kiatchoosakun S, Wongvipaporn C, Tatsanavivat P. Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. *Ann Intern Med* 2004;140:101-105.
149. Iung B, Garbarz E, Michaud P, Mahdhaoui A, Helou S, Farah B, Berdah P, Michel PL, Makita Y, Cormier B, Luxereau P, Vahanian A. Percutaneous mitral commissurotomy for stenosis after surgical commissurotomy: late efficacy and implications for patient selection. *J Am Coll Cardiol* 2000;35:1295-1302.

150. Iung B, Garbarz E, Doutrelant L, Berdah P, Michaud P, Farah B, Mokhtari M, Makita Y, Michel PL, Luxereau P, Cormier B, Vahanian A. Late results of percutaneous mitral commissurotomy for calcific mitral stenosis. *Am J Cardiol* 2000;**85**:1308–1314.
151. Sutaria N, Elder AT, Shaw TRD. Long term outcome of percutaneous mitral balloon valvotomy in patients aged 70 and over. *Heart* 2000;**83**:433–438.
152. Scully HE, Armstrong CS. Tricuspid valve replacement fifteen years of experience with mechanical prostheses and bio-protheses. *J Thorac Cardiovasc Surg* 1995;**109**:1035–1041.
153. Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Long-term outcomes of tricuspid valve replacement in the current era. *Ann Thorac Surg* 2005;**80**:845–850.
154. Rizzoli G, Vendramin I, Nesseris G, Bottio T, Guglielmi C, Schiavon L. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. *Ann Thorac Surg* 2004;**77**:1607–1614.
155. Sancaktar O, Kumbasar SD, Semiz E, Yalcinkaya S. Late results of combined percutaneous balloon valvuloplasty of mitral and tricuspid valves. *Cathet Cardiovasc Diagn* 1998;**45**:246–250.
156. Kar AK, Rath PC, Sinha N, Haridas KK, Dasbiswas A, Kerkar P, Kumar R, Non-Coronary Cardiac Intervention Registry of India, Cardiological Society of India. Noncoronary cardiac interventions. The 3rd report of the Non-Coronary Cardiac Interventions Registry of India. The Cardiological Society of India. *Indian Heart J* 2003;**55**:658–662.
157. Porter A, Shapira Y, Wurzel M, Sulkes J, Vaturi M, Adler Y, Sahar G, Sagie A. Tricuspid regurgitation late after mitral valve replacement: clinical and echocardiographic evaluation. *J Heart Valve Dis* 1999;**8**:57–62.
158. Sugimoto T, Okada M, Ozaki N, Hatakeyama T, Kawahira T. Long-term evaluation of treatment for functional tricuspid regurgitation with regurgitant volume: characteristic differences based on primary cardiac lesion. *J Thorac Cardiovasc Surg* 1999;**117**:463–471.
159. Moss R, Munt B. Injection drug use and right-sided endocarditis. *Heart* 2003;**89**:577–581.
160. Tribouilloy CM, Enriquez-Sarano M, Bailey KR, Tajik AJ, Seward JB. Quantification of tricuspid regurgitation by measuring the width of the vena contracta with Doppler color flow imaging: a clinical study. *J Am Coll Cardiol* 2000;**36**:472–478.
161. Colombo T, Russo C, Ciliberto GR, Lanfranconi M, Bruschi G, Agati S, Vitali E. Tricuspid regurgitation secondary to mitral valve disease: tricuspid annulus function as guide to tricuspid valve repair. *Cardiovasc Surg* 2001;**9**:369–377.
162. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? *Ann Thorac Surg* 2005;**79**:127–132.
163. Rivera R, Duran E, Ajuria M. Carpentier's flexible ring versus De Vega's annuloplasty. A prospective randomized study. *J Thorac Cardiovasc Surg* 1985;**89**:196–203.
164. Oxenham H, Bloomfield P, Wheatley DJ, Lee RJ, Cunningham J, Prescott RJ, Miller HC. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine prostheses. *Heart* 2003;**89**:715–721.
165. Lund O, Bland M. Age and risk corrected impact of mechanical versus biological valves on long-term mortality after aortic valve replacement. *J Thorac Cardiovasc Surg* 2006;**132**:20–26.
166. Grunkemeier GL, Li HH, Naftel DC, Starr A, Rahimtoola SH. Long-term performance of heart valve prostheses. *Curr Probl Cardiol* 2000;**25**:73–156.
167. Rahimtoola SJ. Choice of prosthetic heart valve for adult patients. *J Am Coll Cardiol* 2003;**41**:893–904.
168. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. *J Thorac Cardiovasc Surg* 2002;**123**:715–723.
169. O'Brien MF, Hancock S, Stafford EG. The homograft aortic valve: a 29-year, 99.3% follow-up of 1,022 valve replacements. *J Heart Valve Dis* 2001;**10**:334–344.
170. Elkins RC, Knott-Craig CJ, Ward KE. Pulmonary autograft in children: realized growth potential. *Ann Thorac Surg* 1994;**57**:1387–1392.
171. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. *Arch Intern Med* 2001;**161**:2125–2128.
172. Poli D, Antonucci E, Lombardi A, Boddi V, Gensini GF, Abbate R, Prisco D. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. *Blood Coagul Fibrinolysis* 2003;**14**:269–275.
173. Grunkemeier GL, Jamieson WRE, Miller DC, Starr A. Actuarial versus actual risk of porcine structural valve deterioration. *J Thorac Cardiovasc Surg* 1994;**108**:709–718.
174. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? *Circulation* 2002;**105**:1336–1341.
175. Hung L, Rahimtoola SH. Prosthetic heart valves and pregnancy. *Circulation* 2003;**107**:1240–1246.
176. Fitzmaurice DA, Machin SJ, British Society of Haematology Task Force for Haemostasis Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. *BMJ* 2001;**323**:985–989.
177. Butchart EG, Ionescu A, Payne N, Giddings J, Grunkemeier GL, Fraser AG. A new scoring system to determine thromboembolic risk after heart valve replacement. *Circulation* 2003;**108**(Suppl. II):68–74.
178. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease—native and prosthetic. *Chest* 2004;**126**(Suppl.):457S–482S.
179. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D'Amico R, Beghi C. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. *Circulation* 2004;**110**:496–500.
180. Laplace G, Lafitte S, Labeque JN, Perron JM, Baudet E, Deville C, Roques X, Roudaut R. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. *J Am Coll Cardiol* 2004;**43**:1283–1290.
181. Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, Pony JC, Breton HL, Thomas D, Isnard R, de Gevigney G, Viguier E, Sfihi A, Hanania G, Ghannem M, Mirode A, Nemoz C. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. *Circulation* 1996;**94**:2107–2112.
182. Huth C, Friedl A, Rost A, for the GELIA study investigator group. Intensity of oral anticoagulation after implantation of St Jude Medical aortic prosthesis: analysis of the GELIA database (GELIA 4). *Eur Heart J* 2001;**22**(Suppl. Q):Q33–Q38.
183. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. *Ann Intern Med* 2001;**135**:393–400.
184. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. *Br J Haematol* 2001;**114**:271–280.
185. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;**324**:71–86.
186. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. *N Engl J Med* 1993;**329**:524–529.
187. Chesebro J, Fuster V, Elveback LR. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. *Am J Cardiol* 1983;**51**:1537–1541.
188. Pouleur H, Buyse M. Effects of dipyridamole in combination with anti-coagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. *J Thorac Cardiovasc Surg* 1995;**110**:463–472.
189. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart valve replacement: a meta-analysis. *Am Heart J* 1995;**130**:547–552.
190. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transeophageal echocardiographic study. *J Am Coll Cardiol* 2001;**35**:739–746.
191. Massel D, Little SH. Risks and benefits of adding antiplatelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. *J Am Coll Cardiol* 2001;**37**:569–578.
192. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB. Safety and efficacy of aspirin, clopidogrel and warfarin after coronary stent placement in patients with an indication for anticoagulation. *Am Heart J* 2004;**147**:463–467.
193. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary

- interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. *Eur Heart J* 2005;26:804-847.
194. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH, Turpie AG. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. *J Am Coll Cardiol* 1997;30:1521-1526.
195. Gohlke-Bärwolf C. Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. *Heart* 2000;84:567-572.
196. Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants. A systematic review. *Arch Intern Med* 2003;163:901-908.
197. Wahl MJ. Dental surgery in anticoagulated patients. *Arch Intern Med* 1998;158:1610-1616.
198. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. *Br J Haematol* 2003;123:676-682.
199. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. *Circulation* 2006;113:564-569.
200. Seshadri N, Goldhaber SZ, Elkayam U, Grimm RA, Groce JB III, Heit JA, Spinler SA, Turpie AG, Bosker G, Klein AL. The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. *Am Heart J* 2005;150:27-34.
201. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. *Heart* 2003;89:527-530.
202. Tong AT, Roudaut R, Ozkan M, Sagie A, Shahid MS, Pontes Junior SC, Carreras F, Girard SE, Arnaout S, Stainback RF, Thadhani R, Zoghbi WA, Prosthetic Valve Thrombolysis—Role of Transesophageal Echocardiography (PRO-TEE) Registry Investigators. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. *J Am Coll Cardiol* 2004;43:77-84.
203. Montorsi P, De Bernardi F, Muratori M, Cavoretto D, Pepi M. Role of cine-fluoroscopy, transthoracic, and TEE in patients with suspected prosthetic heart valve thrombosis. *Am J Cardiol* 2000;85:58-64.
204. Roudaut R, Lafitte S, Roudaut MF, Courtault C, Perron JM, Jais C, Pillois X, Coste P, DeMaria A. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. *J Am Coll Cardiol* 2003;41:653-658.
205. Lengyel M, Horstkotte D, Voller H, Mistiaen WP, Working Group Infection, Thrombosis, Embolism Bleeding of the Society for Heart Valve Disease. Recommendations for the management of prosthetic valve thrombosis. *J Heart Valve Dis* 2005;14:567-575.
206. Rizzoli G, Guglielmi C, Toscano G, Pistorio V, Vendramin I, Bottio T, Thiene G, Casarotto D. Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. *Eur J Cardiothorac Surg* 1999;16:74-80.
207. Iung B, Cormier B, Dadez E, Drissi MF, Tsezana R, Viguier E, Caviezel B, Michel PL, Samama M, Vahanian A, Acar J. Small abnormal echos after mitral valve replacement with bileaflet mechanical prostheses: predisposing factors and effect on thromboembolism. *J Heart Valve Dis* 1993;2:259-266.
208. Gueret P, Vignon P, Fournier P, Chabernaude JM, Gomez M, LaCroix P, Bensaid J. TEE for the diagnosis and management of nonobstructive thrombosis of mechanical mitral valve prosthesis. *Circulation* 1995;91:103-110.
209. Butchart EG, Moreno de la Santa P, Rooney SJ, Lewis PA. Arterial risk factors and cerebrovascular events following aortic valve replacement. *J Heart Valve Dis* 1995;4:1-8.
210. Ionescu A, Fraser AG, Butchart EG. Prevalence and clinical significance of incidental paraprosthetic valvar regurgitation: a prospective study using TEE. *Heart* 2003;89:1316-1321.
211. Hussain ST, Devagourou V, Sampath Kumar A. Management of mitral paravalvular leak: therapy or misadventure? *J Thorac Cardiovasc Surg* 2003;126:879-880.
212. Vogt PR, Brunner-LaRocca H, Sidler P, Zund G, Truniger K, Lachat M, Turina M, Turina MI. Reoperative surgery for degenerated aortic bioprostheses: predictors for emergency surgery and reoperative mortality. *Eur J Cardiothorac Surg* 2000;17:134-139.
213. Akins CW, Buckley MJ, Daggett WM, Hilgenberg AD, Vlahakes GJ, Torchiana DF, Madsen JC. Risk of reoperative valve replacement for failed mitral and aortic bioprostheses. *Ann Thorac Surg* 1998;65:1545-1551.
214. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr, American College of Cardiology, American Heart Association. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *J Am Coll Cardiol* 2002;39:542-553.
215. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999;100:1043-1049.
216. O'Keefe JH Jr, Shub C, Rettke SR. Risk of noncardiac surgical procedures in patients with aortic stenosis. *Mayo Clin Proc* 1989;64:400-405.
217. Raymer K, Yang H. Patients with aortic stenosis: cardiac complications in non-cardiac surgery. *Can J Anaesth* 1998;45:855-859.
218. Torsher LC, Shub C, Rettke SR, Brown DL. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. *Am J Cardiol* 1998;81:448-452.
219. Kertai MD, Bountiokos M, Boersma E, Bax JJ, Thomson IR, Sozzi F, Klein J, Roelandt JR, Poldermans D. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing non-cardiac surgery. *Am J Med* 2004;116:8-13.
220. Boon NA, Bloomfield P. The medical management of valvar heart disease. *Heart* 2002;87:395-400.
221. Bradley D, Creswell LL, Hoghe ChW, Epstein AE, Prystowsky EN, Daoud EG. Pharmacologic prophylaxis. American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation after Cardiac Surgery. *Chest* 2005;128:395-475.
222. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med* 1999;341:1789-1794.
223. Thorne SA. Pregnancy in heart disease. *Heart* 2004;90:450-456.
224. Oakley C, Child A, Iung B, Presbitero P, Tornos P. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. *Eur Heart J* 2003;24:761-781.
225. Siu SC, Sermer M, Harrison DA, Grigoriadis E, Liu G, Sorensen S, Smallhorn JF, Farine D, Amankwah KS, Spears JC, Colman JM. Risk and predictors for pregnancy-related complications in women with heart disease. *Circulation* 1997;96:2789-2794.
226. Hameed A, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, Goodwin I, Zapadinsky N, Elkayam U. The effect of valvular heart disease on maternal and fetal outcome during pregnancy. *J Am Coll Cardiol* 2001;37:893-899.
227. Malhotra M, Sharma JB, Tripathii R, Arora P, Arora R. Maternal and fetal outcome in valvular heart disease. *Int J Gynaecol Obstet* 2004;84:11-16.
228. Rossiter JP, Repke JT, Morales AJ, Murphy EA, Pyeritz RE. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. *Am J Obstet Gynecol* 1995;173:1599-1606.
229. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. *Arch Intern Med* 2000;160:191-196.
230. Elkayam U. Valvular heart disease and pregnancy. Part II: Prosthetic valves. *J Am Coll Cardiol* 2005;46:403-410.
231. Arnoni RT, Arnoni AS, Bonini RC, de Almeida AF, Neto CA, Dinkhuysen JJ, Issa M, Chacur P, Paulista PP. Risk factors associated with cardiac surgery during pregnancy. *Ann Thorac Surg* 2003;76:1605-1608.
232. Presbitero P, Prever SB, Brusca A. Interventional cardiology in pregnancy. *Eur Heart J* 1996;17:182-188.